Gene therapy for focal epilepsy
Part of Brain & nervous system clinical trials.
This trial tests a gene therapy given directly into the brain to quiet the overactive nerve cells that cause seizures. It's an option for adults with focal epilepsy who are already planning surgery and haven't found relief from medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have focal epilepsy that hasn't been controlled by at least two medications.
- You are being evaluated for brain surgery to remove the specific area where your seizures start.
- You are 18 or older and expected to live at least 5 more years.
- You live within 1 hour of a hospital that can handle emergency brain surgery.
- You don't have cancer, a vascular brain lesion, active HIV, or untreated psychiatric illness.
- You agree to use effective birth control during the trial and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genes, proteins, and other body chemicals in people with drug-resistant epilepsy (seizures that continue despite trying multiple medications). By studying samples from people who are already having SEEG surgery to find where seizures start, researchers hope to discover new clues about what makes epilepsy hard to treat. The results may help develop better tests or treatments in the future.
This study tests a personalized, non-invasive brain stimulation method called tDCS for people with drug-resistant epilepsy that starts in one part of the brain. It aims to reduce seizures in those who cannot have surgery or have not been helped by surgery.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
This trial tests a new cell-based treatment for people with epilepsy that has not improved with standard medications. The treatment aims to reduce seizures in patients with a specific type of epilepsy originating from one side of the brain.
This trial tests a new cell therapy (NRTX-1001) for people with epilepsy that starts in both sides of the brain's temporal lobes and doesn't get better with medication. It aims to reduce or stop seizures.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
Hear when a new Drug Resistant Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.